bioTheranostics, Prime Health Services sign contract to expand genomic tests

bioTheranostics, Inc.Apr 9 2014

bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, has signed a contract with Prime Health Services, Inc., a national preferred provider organization network, to cover the company's genomic tests for breast cancer patients and patients with metastatic disease.

Prime Health Services members in all 50 states now have access to bioTheranostics' full suite of molecular-based diagnostic, prognostic, and predictive cancer tests, including both the Breast Cancer Index^SM, which quantifies risk of recurrence of early stage, estrogen receptor-positive breast cancer, and CancerTYPE ID^®, a genomic test for accurate diagnosis of metastatic cancer.

Richard Ding, CEO of bioTheranostics, said, "As an early adopter of the Breast Cancer Index, Prime Health Services is leading the way in improving breast cancer management. This breakthrough test allows oncologists to help patients with estrogen receptor-positive breast cancer better understand their risk of recurrence across a full 10-year time frame, as well as their potential benefit from extended endocrine therapy. We are delighted that Prime Health will be offering this test to members and look forward to working with additional payors to make our molecular tests broadly available to support improved cancer management nationwide."

Ding said that the contract with Prime Health Services is one of several agreements that bioTheranostics has signed with national preferred provider organization networks this year, providing more than 91 million covered members with access to both the Breast Cancer Index and CancerTYPE ID tests.

The Breast Cancer Index is a second-generation biomarker that addresses unmet clinical needs by accurately predicting both early (0-5 years) and late (5-10 years) distant recurrence, as well as benefit from extended endocrine therapy. Statistics show that the majority (about two-thirds) of breast cancer patients are estrogen receptor positive, and the risk of late distant recurrence remains a substantial concern, with about 50 percent of recurrences occurring after five years.

The CancerTYPE ID, an industry-leading molecular cancer classifier, predicts tumor type in patients with metastatic cancers, which affect hundreds of thousands of patients in the United States each year and are among the most difficult to diagnose and treat. The CancerTYPE ID test is supported by clinical evidence confirming its diagnostic accuracy, clinical utility in tumor classification, and impact on patient outcomes.